A detailed history of Parallel Advisors, LLC transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Parallel Advisors, LLC holds 22 shares of JANX stock, worth $1,106. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22
Holding current value
$1,106
% of portfolio
0.0%

Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$35.29 - $50.26 $776 - $1,105
22 New
22 $0
Q3 2023

May 20, 2024

BUY
$9.56 - $14.0 $0 - $0
0 New
0 $0
Q3 2023

Nov 13, 2023

BUY
$9.56 - $14.0 $0 - $0
0 New
0 $0

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.1B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Parallel Advisors, LLC Portfolio

Follow Parallel Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Parallel Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Parallel Advisors, LLC with notifications on news.